Method for predicting the risk of drugdrug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

Xenobiotica

Volumn 39, Issue 6, 2009, Pages 430-443

  Tachibana, T ^a   Kato, M ^a   Watanabe, T ^b   Mitsui, T ^a   Sugiyama, Y ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Absorption; CYP3A4; Drugdrug interaction; Human; Intestine; P glycoprotein

Indexed keywords

2 [4 [2 (5 TETRAZOLYLMETHYL)BENZYLOXY]PHENOXYMETHYL]QUINOLINE; APREPITANT; ASCORBYL PALMITATE; ATORVASTATIN; BICALUTAMIDE; CELIPROLOL; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; DOCETAXEL; FELODIPINE; FEXOFENADINE; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; GLYCOPROTEIN P; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; MIDAZOLAM; NEFAZODONE; PACLITAXEL; RANITIDINE; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; TALINOLOL; TRIAZOLAM; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXCRETION; DRUG INHIBITION; DRUG INTERACTION; DRUG INTERACTION NUMBER; DRUG METABOLISM; DRUG SOLUBILITY; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; INTESTINE; PREDICTOR VARIABLE; RISK ASSESSMENT; BIOAVAILABILITY; DRUG ANTAGONISM; ENZYME SPECIFICITY; ENZYMOLOGY; HUMAN; INTESTINE ABSORPTION; METHODOLOGY; PHARMACOLOGY; RISK FACTOR; SOLUBILITY;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; P-GLYCOPROTEIN; PHARMACOLOGY; RISK FACTORS; SOLUBILITY; SUBSTRATE SPECIFICITY;

EID: 69249202502     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250902846252     Document Type: Article

References (122)

1. Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. (1983). Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl) 80(3):275-278
2. Ahonen J, Olkkola KT, Neuvonen PJ. (1995). Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40(3):270-272
3. Ahonen J, Olkkola KT, Neuvonen PJ. (1997). Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 51(5):415-419
4. Amidon GL, Lennernas H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceut Res 12(3):413-420
5. Back DJ, Tjia JF, Abel SM. (1992). Azoles, allylamines and drug metabolism. Br J Dermatol 126 Suppl. 39:14-18
6. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. (1998). The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54(1):53-58
7. Backman JT, Wang JS, Wen X, Kivisto KT, Neuvonen PJ. (1999). Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. Clin Pharmacol Ther 66(4):401-407
8. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. (1995). Co-administration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 15(5):320-326
9. Bernsdorf A, Giessmann T, Modess C, Wegner D, Igelbrink S, Hecker U, Haenisch S, Cascorbi I, Terhaag B, Siegmund W. (2006). Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 61(4):440-450
10. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. (2000). Atorvastatin co- administration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 40(1):91-98
11. Brinkman K, Huysmans F, Burger DM. (1998). Pharmacokinetic interaction between saquinavir and cyclosporine. Ann Intern Med 129(11):914-915
12. British Pharmacopoeia (2008). London, UK: British Pharmacopeia Commission.
13. Brunton LL, Lazo JS, Parker KL, editors. (2005). Goodman and Gilmans's the pharmacological basis of therapeutics. 11th ed. New York, NY: McGraw-Hill.
14. Butman SM, Wild JC, Nolan PE, Fagan TC, Finley PR, Hicks MJ, Mackie MJ, Copeland JG III (1991). Prospective study of the safety and financial benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J Heart Lung Transplant 10(3):351-358
15. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. (1991). Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 51(5):1014-1018
16. Carlton RA, Difeo TJ, Powner TH, Santos I, Thompson MD. (1996). Preparation and characterization of polymorphs for an LTD4 antagonist, RG 12525. J Pharm Sci 85(5):461-467
17. Caruso FS, Doshan HD, Hernandez PH, Costello R, Applin W, Neiss ES. (1985). Celiprolol: pharmacokinetics and duration of pharmacodynamic activity. Br J Clin Pract Suppl. 40:12-16
18. Cockshott ID. (2004). Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 43(13):855-878
19. Cox SR, Kroboth PD, Anderson PH, Smith RB. (1986). Mechanism for the interaction between triazolam and cimetidine. Biopharm Drug Dispos 7(6):567-575
20. Cummins CL, Jacobsen W, Benet LZ. (2002). Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300(3):1036-1045
21. Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, Gillespie B, Sahajwalla C, Huang SM, Lesko LJ. (1999). FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 39(9):899-910.
22. Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. (2002). Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 72(3):247-255
23. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R. (2004). Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60(4):237-246
24. Einolf HJ. (2007). Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37(10-11):1257-1294
25. Elliott P, Dundee JW, Elwood RJ, Collier PS. (1984). The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. Eur J Anaesthesiol 1(3):245-251
26. Engle K, Borza S, Philippi E, editors. (2008). Physician's desk reference 2008. 62nd ed. New Jersey, USA: Thomson Healthcare.
27. Fayer JL, Zannikos PN, Stevens JC, Luo Y, Sidhu R, Kirkesseli S. (2001). Lack of correlation between in vitro inhibition of CYP3Amediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity. J Clin Pharmacol 41(3):305-316
28. Fee JP, Collier PS, Howard PJ, Dundee JW. (1987). Cimetidine and ranitidine increase midazolam bioavailability. Clin Pharmacol Ther 41(1):80-84
29. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau DP. (2003). Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 35(8):2873-2877
30. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. (1997). Tacrolimus oral bioavailability doubles with co-administration of ketoconazole. Clin Pharmacol Ther 62(1):41-49
31. Foradori A, Mezzano S, Videla C, Pefaur J, Elberg A. (1998). Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Transplant Proc 30(5):1685-1687
32. Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. (1988). Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. J Clin Pharmacol 28(3):228-233
33. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. (1995). The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58(1):15-19
34. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. (2006). Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98(1):79-85.
35. Greenblatt DJ, Locniskar A, Scavone JM, Blyden GT, Ochs HR, Harmatz JS, Shader RI. (1986). Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. Anesth Analg 65(2):176-180
36. Greenblatt DJ, Von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. (2000). Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24(2):129-136
37. Greenblatt DJ, Wright CE, Von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI. (1998). Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 64(3):237-247 (Pubitemid 28462284)
38. Grub S, Bryson H, Goggin T, Ludin E, Jorga K. (2001). The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 57(2):115-121
39. Guengerich FP, Kim DH. (1990). In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11(12):2275-2279
40. Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM. (1998). Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63(4):453-464
41. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. (2001). Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 45(12):3445-3450
42. Interview form of Nelfinavir Mesilate. 2nd ed. (2005). Tokyo, Japan: Tolii Pharmaceutical Co. Ltd.
43. Interview form of Saquinavir Mesilate. 12th ed. (2006). Tokyo, Japan: Chugai Pharmaceutical Co. Ltd.
44. Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. (2001). A comparison of the effects of 3-hydroxy- 3- methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 29(3):282-288
45. Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57(4):473-486
46. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y, Ueda K, Itoh T, Sugiyama Y. (2002). Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4(4):E25.
47. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. (1998). Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50(3):387-412.
48. Jalava KM, Olkkola KT, Neuvonen PJ. (1997). Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 61(4):410-415
49. Jensen P, Lehne G, Fauchald P, Simonsen S. (1996). Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection. Acta Derm Venereol 76(4):280-281
50. Kantola T, Kivisto KT, Neuvonen PJ. (1998). Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64(1):58-65.
51. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K et al. (2003). The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18(6):365-372
52. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, Sugiyama Y. (2008). The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharmaceut Res 25(8):1891-1901
53. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, Rost KL. (1999). Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 66(4):391-400.
54. Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB. (1995). Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. J Clin Psychopharmacol 15(4):259-262
55. Kunta JR, Sinko PJ. (2004). Intestinal drug transporters: in vivo function and clinical importance. Current Drug Metabolism 5(1):109-124
56. Lacarelle B, Rahmani R, De Sousa G, Durand A, Placidi M, Cano JP. (1991). Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fund Clin Pharmacol 5(7):567-582
57. Lam YW, Alfaro CL, Ereshefsky L, Miller M. (2003). Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43(11):1274-1282
58. Lee CY, Ford N, Rowland M. ASCPT 2008 Annual meeting late breaking oral session LBIII-A; [cited 2008 Dec 9]. Available at: http://www.ascpt.org/ annualmeeting2008/presentations/april52008/late-breaking-oral-session-LBIIIA. pdf/.
59. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. (2002). Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 72(6):718-728
60. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. (2005). Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5(9):2236-2243
61. Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. (2006). The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 79(3):218-230
62. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. (2003). Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 73(3):192-198
63. Lin JH, Chiba M, Baillie TA. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51(2):135-158
64. Long CC, Hill SA, Thomas RC, Johnston A, Smith SG, Kendall F, Finlay AY. (1994). Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. J Invest Dermatol 102(5):740-743
65. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. (1996). Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol 50(3):203-208
66. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA. (2003). Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 74(2):150-156
67. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH. (2001a). Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84(1):42-47
68. Malingre MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens JH. (2001b). Co-administration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 19(4):1160-1166
69. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. (2000). Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 68(4):391-400.
70. McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, Brucker MJ, Miller-Stein C, Osborne B, Waldman S. (1999). Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol 39(12):1212-1220
71. McDonnell CG, Shorten G, Van Pelt FN. (2005). Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia 60(8):747-753
72. McEvoy GK, Snow EK, Pharm BS, editors. (2008). AHFS drug information 2008. Maryland, USA: American Society of Health-System Pharmacists.
73. Meerum Terwogt JM, Malingre MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, Van Tellingen O, Swart M, Schellens JH. (1999). Co-administration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5(11):3379-3384
74. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, Gibbons SE, Breckenridge AM, Back DJ. (1997). Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. Aids 11(4):F29-33.
75. Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. (1991). Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 52(6):1086-1087
76. Mizuno N, Sugiyama Y. (2002). Drug transporters: their role and importance in the selection and development of new drugs. Drug Metab Pharmacokinet 17(2):93-108.
77. Neuvonen PJ, Varhe A, Olkkola KT. (1996). The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 60(3):326-331
78. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316(1):336-348
79. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. (2005). In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78(6):582-592
80. O'Connor-Semmes RL, Kersey K, Williams DH, Lam R, Koch KM. (2001). Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. Clin Pharmacol Ther 70(2):126-131
81. Oh DM, Curl RL, Amidon GL. (1993). Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharmaceut Res 10(2):264-270
82. Olkkola KT, Ahonen J, Neuvonen PJ. (1996). The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82(3):511-516
83. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ. (1993). A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53(3):298-305.
84. Olkkola KT, Backman JT, Neuvonen PJ. (1994). Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55(5):481-485
85. Ozawa N, Shimizu T, Morita R, Yokono Y, Ochiai T, Munesada K, Ohashi A, Aida Y, Hama Y, Taki K, Maeda K, Kusuhara H, Sugiyama Y. (2004). Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharmaceut Res 21(11):2133-2134
86. Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. (1985). Pharmacokinetic consequences of long term co-administration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol 23(8):447-451
87. Prueksaritanont T, Vega JM, Rogers JD, Gagliano K, Greenberg HE, Gillen L, Brucker MJ, McLoughlin D, Wong PH, Waldman SA. (2000). Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol 40(11):1274-1279
88. Renders L, Haas CS, Liebelt J, Oberbarnscheidt M, Schocklmann HO, Kunzendorf U. (2003). Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. Br J Clin Pharmacol 56(2):214-219
89. Riddell JG, Shanks RG, Brogden RN. (1987). Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs 34(4):438-458
90. Rostami-Hodjegan A, Tucker GT. (2004). 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug- drug interactions. Drug Disc Today Tech 1:441-448.
91. Salonen M, Aantaa E, Aaltonen L, Kanto J. (1986). Importance of the interaction of midazolam and cimetidine. Acta Pharmacol Toxicol (Copenh) 58(2):91-95
92. Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE. (2004). Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 32(11):1287-1292
93. Schwarz UI, Gramatte T, Krappweis J, Berndt A, Oertel R, Von Richter O, Kirch W. (1999). Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin Pharmacol Ther 65(3):283-290
94. Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W. (2000). P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38(4):161-167 (Pubitemid 30193611)
95. Shimizu M, Uno T, Sugawara K, Tateishi T. (2006). Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 61(5):538-544
96. Simpson K, Jarvis B. (2000). Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59(2):301-321
97. Stern RH, Gibson DM, Whitfield LR. (1998). Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol 53(6):475-478
98. Stocker H, Herzmann C, Breske A, Kruse G, Berger M, Schulbin H, Hill A, Steinmuller J, Becker M, Arasteh K, Kurowski M. (2007). Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration. J Antimicrob Chemother 59(3):560-564
99. Terhaag B, Gramatte T, Richter K, Voss J, Feller K. (1989). The biliary elimination of the selective beta-receptor blocking drug talinolol in man. Int J Clin Pharmacol Ther Toxicol 27(4):170-172
100. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. (1996). Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59(5):491-502.
101. Toda F, Tanabe K, Ito S, Shinmura H, Tokumoto T, Ishida H, Toma H. (2002). Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. Transplant Proc 34(5):1733-1735
102. Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV, Kasiske BL. (1990). The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. Ther Drug Monit 12(4):321-328
103. Tsunoda SM, Velez RL, Von Moltke LL, Greenblatt DJ. (1999). Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66(5):461-471
104. Tuteja S, Alloway RR, Johnson JA, Gaber AO. (2001). The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71(9):1303-1307
105. Uno T, Shimizu M, Sugawara K, Tateishi T. (2006). Lack of dose- dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos 34(11):1875-1879
106. Van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW. (2006). Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46(7):758-767
107. Vanderveen RP, Jirak JL, Peters GR, Cox SR, Bombardt PA. (1991). Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin Pharm 10(7):539-543
108. Varhe A, Olkkola KT, Neuvonen PJ. (1994). Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56(6 Pt 1):601-607
109. Varhe A, Olkkola KT, Neuvonen PJ. (1996a). Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 42(4):465-470
110. Varhe A, Olkkola KT, Neuvonen PJ. (1996b). Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 41(4):319-323 (Pubitemid 26114819)
111. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. (2003). P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48(4):347-359
112. Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, Jaillon P, Funck-Brentano C, Trugnan G, Becquemont L. (2003). Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 73(1):51-60.
113. Vickers AE, Sinclair JR, Zollinger M, Heitz F, Glanzel U, Johanson L, Fischer V. (1999). Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug- drug interactions. Drug Metab Dispos 27(9):1029-1038
114. Villikka K, Varis T, Backman JT, Neuvonen PJ, Kivisto KT. (2001). Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. Eur J Clin Pharmacol 57(6-7):457-460
115. Von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. (1996). Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276(2):370-379
116. Wang JS, Backman JT, Kivisto KT, Neuvonen PJ. (2000). Effects of metronidazole on midazolam metabolism in vitro and in vivo. Eur J Clin Pharmacol 56(8):555-559
117. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. (2000). Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68(1):6-12.
118. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P. (1996). Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13(4):514-522
119. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN. (1992). A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 12(2):103-106
120. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. (2005). Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 77(1):17-23.
121. Yu LX. (1999). An integrated model for determining causes of poor oral drug absorption. Pharmaceut Res 16(12):1883-1887
122. Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. (2008). A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38(7-8):709-724